Company Profile
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest News
3Shape's TRIOS MOVE Pro Scanner Cart Wins Red Dot 2026 Design Award
AI Usage Among 7th Gen Galaxy Foldables Users Grows in Southeast Asia and Oceania as Mobile Continues to be the Primary Gateway to AI
Take Five: A crude summer
Bank of England to keep rate steady despite oil and gas price rebound
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Website | https://www.novonordisk.com |
| Audit Risk | 2 |
| Board Risk | 5 |
| Overall Risk | 3 |
| Market Cap | 1.43T |
| Trailing P/E | 11.82 |
| Forward P/E | 15.07 |
| Dividend Rate | 15.9 |
| Dividend Yield | 4.96% |
| Trailing Annual Div. Rate | 11.7 |
| Trailing Annual Div. Yield | 3.65% |
| Trailing EPS | 27.41 |
| Forward EPS | 21.5 |
| Book Value | 45.71 |
| Price-to-Book | 7.09 |
| Enterprise-to-Revenue | 4.73 |
| Enterprise-to-EBITDA | 8.91 |
| Ex-Dividend Date | 03/27/2026 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | 08/05/2026 |
| Earnings Average | 5.04 |
| Earnings Low | 4.66 |
| Earnings High | 5.56 |
| Revenue Average | 71.39B |
| Revenue Low | 69.60B |
| Revenue High | 72.86B |